Robert Mutter, SABCS 2022: Conventional versus hypofractionated post-mastectomy proton radiotherapy
The phase II randomized trial of conventional versus hypofractionated proton radiotherapy investigated whether condensing treatment to 15 fractions would be safe based on evidence that breast cancer is more sensitive to higher dose fractions than surrounding normal tissues. In this touchONCOLOGY interview, we speak with Dr Robert Mutter (Mayo Clinic Rochester, MN, United States) provides an overview of this trial and the impact of the findings.
The abstract entitled ‘Phase II randomized trial of conventional versus hypofractionated post-mastectomy proton radiotherapy’ was presented at San Antonio Breast Cancer Symposium (SABCS), 06–10, December, 2022.
- What was the reason for the hypothesis that condensing treatment to 15 fractions would be safe, as opposed to conventional fractionation? (0:15)
- What were the methodology and eligibility criteria of your study? (2:09)
- What were the findings in terms of disease control, tolerability and reconstruction outcomes? (03:34)
- What will be the impact of these findings on future clinical trial design? (4:42)
Disclosures: Robert Mutter has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen
Filmed as a highlight of SABCS 2022
Access more content on Breast Cancer
Share this Video
Related Videos In Breast Cancer
Sara Hurvitz, SABCS 2022: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2+ metastatic breast cancer: DESTINY-Breast03
Trastuzumab deruxtecan (T-DXd) is approved in the United States and European Union for use in patients with HER2+ unresectable/metastatic breast cancer. Approval was based on the randomized, multicenter, open-label, phase III DESTINY-Breast03 (NCT03529110) trial. In this interview we discuss with Dr Sara Hurvitz (David Geffen School of Medicine, UCLA Los Angeles, CA, USA) updated data […]
Erika Hamilton, SABCS 2022: Trastuzumab deruxtecan and pertuzumab in HER2+ metastatic breast cancer
Preclinical findings have suggested that when used in combination with anticancer treatments, trastuzumab deruxtecan (T-Dxd) could improve treatment efficacy in HER2+ metastatic breast cancer (mBC). In this interview we discuss with Dr Erika Hamilton (Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN) preliminary data from the dose expansion phase of the DESTINY-Breast07 (DB-07) (NCT04538742) trial. […]
Sudeep Gupta, SABCS 2022: Addition of platinum to neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial
The impact of adding platinum on long-term outcomes in triple-negative breast cancer (TNBC) has not been definitively established. The controlled, single-centre, phase III study conducted by Tata Memorial Hospital in Mumbai, India evaluated the efficacy and toxicity of adding platinum to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. In this touchONCOLOGY interview, we speak […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!